Morgan Stanley Bria Cell Therapeutics Corp. Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$5.72 - $7.58 $25,688 - $34,041	4,491 Added 6.35%	75,228 $482,000
Q1 2023 May 15, 2023	BUY	$4.59 - $7.99 $306,671 - $533,835	66,813 Added 1702.68%	70,737 $526,000
Q4 2022 Feb 14, 2023	BUY	$4.28 - $6.03 $4,053 - $5,710	947 Added 31.81%	3,924 $17,000
Q3 2022 Nov 14, 2022	BUY	$3.0 - $8.31 $381 - $1,055	127 Added 4.46%	2,977 $17,000
Q2 2022 Oct 27, 2022	SELL	$4.28 - $11.9 $74,506 - $207,155	-17,408 Reduced 85.93%	2,850 $16,000

Q2 2022 Aug 15, 2022	SELL	$4.28 - $11.9 $74,506 - $207,155	-17,408 Reduced 85.93%	2,850 $16,000
Q1 2022 Oct 27, 2022	BUY	$5.91 - $10.14 $102,881 - $176,517	17,408 Added 610.81%	20,258 $206,000
Q1 2022 May 13, 2022	BUY	$5.91 - $10.14 $70,689 - $121,284	11,961 Added 144.16%	20,258 $206,000
Q4 2021 Feb 14, 2022	BUY	$7.1 - $10.61 $7,355 - $10,991	1,036 Added 14.27%	8,297 $68,000
Q3 2021 Nov 15, 2021	BUY	$4.4 - $9.28 $31,948 - $67,382	7,261 New	7,261 $59,000

Ticker BCTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,518,000
Market Cap $16M
Description
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.